Researcher
Sileny Han
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Oct 2017 → 10 Jun 2018 - Gynaecological Oncology (Division)
Member
From1 Aug 2010 → Today
Projects
1 - 2 of 2
- Sexuality and breastcancerFrom1 Oct 2020 → TodayFunding: Nonprofit institution or equivalents
- breastcancer and sexualityFrom25 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 102
- Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.(2024)
Authors: Sileny Han
Pages: 168 - 177 - A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or endometrial cancer(2023)
Authors: Sileny Han
Pages: 110 - 118 - Navigating next-generation HR+ /HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression(2023)
Authors: Patrick Neven, Sileny Han, Yannick Van Herck, Hans Wildiers
- European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors(2023)
Authors: Frédéric Amant, Sileny Han
Pages: 1621 - 1626 - Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features(2023)
Authors: Beppe Floris, Kristel Van Calsteren, Patrick Neven, Sileny Han, Daniela Annibali, Diether Lambrechts, Liesbeth Lenaerts, Frédéric Amant
Pages: 3729 - 3743 - Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer(2023)
Authors: Karen Van Baelen, Ha Linh Nguyen, François Richard, Maxim De Schepper, Tatjana Geukens, Sileny Han, Thaïs Baert, Hans Wildiers, Ann Smeets, Ines Nevelsteen, et al.
- RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study(2023)
Authors: Josephine Van Cauwenberge, Kristien Borremans, Sileny Han, Annouschka Laenen, Patrick Neven
Pages: 998 - 999 - PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial(2023)
Authors: Liselore Loverix, Ignace Vergote, Pieter Busschaert, Tom Venken, Bram Boeckx, Hilde Brems, Els Van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, et al.
Pages: 131 - 139 - The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study(2023)
Authors: Patrick Neven, Beppe Floris, Eva Oldenburger, Sileny Han, Chantal Van Ongeval, Ann Smeets, Hans Wildiers, Nele Laudus, Els Dequeker
Pages: E273 - E280 - Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study(2023)
Authors: Eva Oldenburger, Albert Wolthuis, Els Van Nieuwenhuysen, Patrick Neven, Ignace Vergote, Sileny Han
Pages: 1539 - 1545